Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Rating of “Hold” from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have earned an average rating of “Hold” from the twenty-one research firms that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $111.53.

Several research analysts recently weighed in on the stock. Morgan Stanley reduced their price target on shares of Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price objective on shares of Zimmer Biomet and gave the company a “buy” rating in a report on Tuesday, May 6th. JPMorgan Chase & Co. cut their price objective on shares of Zimmer Biomet from $128.00 to $105.00 and set an “overweight” rating for the company in a report on Tuesday, May 6th. Wells Fargo & Company cut their price objective on shares of Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a report on Tuesday, May 6th. Finally, Raymond James cut their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an “outperform” rating for the company in a report on Tuesday, May 6th.

Zimmer Biomet Trading Up 0.6%

Shares of Zimmer Biomet stock opened at $92.47 on Wednesday. The firm has a 50-day simple moving average of $97.95 and a two-hundred day simple moving average of $104.07. The company has a market cap of $18.30 billion, a P/E ratio of 20.78, a price-to-earnings-growth ratio of 1.95 and a beta of 0.72. Zimmer Biomet has a fifty-two week low of $89.22 and a fifty-two week high of $116.71. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. The firm had revenue of $1.91 billion during the quarter, compared to the consensus estimate of $1.89 billion. During the same quarter in the prior year, the firm earned $1.94 EPS. The company’s revenue for the quarter was up 1.1% on a year-over-year basis. As a group, equities analysts predict that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, June 26th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.04%. Zimmer Biomet’s payout ratio is currently 21.24%.

Hedge Funds Weigh In On Zimmer Biomet

Hedge funds have recently made changes to their positions in the stock. Stonebridge Financial Group LLC acquired a new stake in Zimmer Biomet during the 4th quarter worth approximately $25,000. Garde Capital Inc. acquired a new stake in Zimmer Biomet during the 1st quarter worth $29,000. Washington Trust Advisors Inc. purchased a new position in Zimmer Biomet during the 1st quarter worth $30,000. Columbia River Financial Group LLC purchased a new position in Zimmer Biomet during the 1st quarter worth $30,000. Finally, Menard Financial Group LLC purchased a new position in Zimmer Biomet during the 4th quarter worth $30,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.